This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antisense Oligonucleotides Market

Antisense Oligonucleotides are the Promising Elixir for Several Disorders. Get to Know the Key Trends

Antisense Oligonucleotides Market by Drug, Indication, Application & Region - Forecast 2022 - 2032

Antisense Oligonucleotides Market Outlook (2022-2032)

[306 Pages Report] The global antisense oligonucleotides market is projected to amass revenue of around US$ 5,659.2 million by 2032, up from US$ 1,921.6 million in 2022 moving forward with a CAGR of 10.3% during the forecast period.

The antisense oligonucleotides adoption trends are significantly swayed by the fact that they offer promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics, propelling the market growth. They can target a particular malfunctioning gene, interfere with RNA function at cellular level, and can also be silenced or modulated and the same is catching the attention of market players.

The rising demand for antisense oligonucleotides can be attributed to the aid provided by it in modifying immune system that facilitates treatment of a wide range of autoimmune disorders – that cannot be treated with available drugs.

Report Attribute

Details

Antisense Oligonucleotides Market Value (2022)

US$ 1,921.6 million

Antisense Oligonucleotides Market Anticipated Forecast Value (2032)

US$ 5,659.2 million

Antisense Oligonucleotides Market Projected Growth Rate (2022-2032)

10.3%

It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.

Moreover, the market enhanced by the minimal side effects of antisense oligonucleotides, which can be controlled with ease as compared to other class of drugs.

The antisense oligonucleotides market has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 – which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).

However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.

However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes for infant mortality with no approved treatments.

Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the antisense oligonucleotides market outlook is positively influenced by the leadings players in the market and the amount of research and development investments.

Customize this Report

Let us know your requirement to get
100% FREE customization

What Factors are Shaping the Antisense Oligonucleotides Market?

Strong pipeline of antisense oligonucleotides and increased focused on large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides market size.

Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level is further contributing to the growth of the global antisense oligonucleotides market.

However, the global antisense oligonucleotides market is grappling with numerous challenges related to diversity of oligonucleotides, delivery, and regulatory complexity.

Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within target cells is still one of the major challenges hindering the growth of the global antisense oligonucleotides market. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the antisense oligonucleotides market statistics.

Why is North America Expected to Dominate the Antisense Oligonucleotides Market?

North America clearly dominates the global antisense oligonucleotides market due to a strong product pipeline and increasing number of FDA approvals in the region, contributing to the region’s antisense oligonucleotides market share of 56% in 2022.

For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the United States in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Growth Prospects for the Europe Antisense Oligonucleotides Market?

In 2022, the Europe antisense oligonucleotides market is likely to capture a share of 10.0%. In order to improve their product portfolio for antisense oligonucleotides, major players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the antisense oligonucleotides market growth in Europe.

For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company Astra Zeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market grow to some level..

How is the Start-Up Ecosystem in the Antisense Oligonucleotides Market?

While there are many organizations working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are emerging as well which are shaping the market trends.

Examples:

  • RNA-targeting biopharmaceuticals are being created by the US-based start-up Arrakis Therapeutics.

The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.

These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.

  • Antisense RNA therapies are created by the Spanish start-up ARTHEx Biotech for hereditary illnesses.

The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

How Strong is the Competition in the Antisense Oligonucleotides Market?

The market for antisense oligonucleotides is fairly consolidated, with a few number of competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.

A couple of recent developments in the antisense oligonucleotides market are:

  • AmpTec, a renowned German company that specialises in mRNA contract development and manufacture, was purchased by MilliporeSigma (US) (CDMO).

The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.

  • oPools- oligo pools, a collection of 350-nucleotide-long, high-quality DNA oligonucleotides, was introduced by Integrated DNA Technology (US).

Key player:

  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Biogen
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Isarna Therapeutics GmbH
  • Arrowhead Pharmaceuticals, Inc.
  • Alantic Pharmaceuticals, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • Gene Signal International SA
  • GlaxoSmithKline plc
  • Geron Corporation
  • Gradalis
  • ICO Therapeutics
  • Aptose Biosciences
  • Marina Biotech
  • miRagen Therapeutics, Inc.
  • Synlogic, Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Pharmaxis Ltd, Regulus Therapeutics Inc.
  • Rexahn Pharmaceuticals, Inc.
  • RXi Pharmaceuticals

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 10.3% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug
  • Indication
  • Application
  • Region

Regions Covered

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
  • Europe

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Biogen
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Isarna Therapeutics GmbH
  • Arrowhead Pharmaceuticals, Inc.
  • Alantic Pharmaceuticals, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • Gene Signal International SA
  • GlaxoSmithKline plc
  • Geron Corporation
  • Gradalis
  • ICO Therapeutics
  • Aptose Biosciences
  • Marina Biotech
  • miRagen Therapeutics, Inc.
  • Synlogic, Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Pharmaxis Ltd, Regulus Therapeutics Inc.
  • Rexahn Pharmaceuticals, Inc.
  • RXi Pharmaceuticals

Key Segments Profiled in the Antisense Oligonucleotides Market Survey

By Drug:

  • Approved Drugs
  • Pegaptanib
  • Mipomersen
  • Eteplirsen
  • Pipeline Analysis

By Indication:

  • Ocular Diseases
  • Cancer
  • Diabetes
  • Amyotrophic Lateral Sclerosis (ALS)
  • Duchenne Muscular Dystrophy
  • Spinal Muscular Atrophy
  • Others

By Application:

  • Basic Research
  • Genomics
  • Target Validation
  • Drug Discovery

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
  • Europe

Frequently Asked Questions

The global antisense oligonucleotides market is likely to advance at 10.3% CAGR (2022-2032).

North America is projected to lead the antisense oligonucleotides market with a share of 56% in 2022.

Antisense oligonucleotides market is anticipated to account for US$ 5,659.2 million by 2032.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Drug

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug, 2022-2032

        5.3.1. Approved Drugs

            5.3.1.1. Pegaptanib

            5.3.1.2. Mipomersen

            5.3.1.3. Eteplirsen

        5.3.2. Pipeline Analysis

    5.4. Y-o-Y Growth Trend Analysis By Drug, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug, 2022-2032

6. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Ocular Diseases

        6.3.2. Cancer

        6.3.3. Diabetes

        6.3.4. Amyotrophic Lateral Sclerosis (ALS)

        6.3.5. Duchenne Muscular Dystrophy

        6.3.6. Spinal Muscular Atrophy

        6.3.7. Others

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

7. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By End Usr

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End Usr , 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End Usr , 2022-2032

        7.3.1. Basic Research

        7.3.2. Genomics

        7.3.3. Target Validation

        7.3.4. Drug Discover

    7.4. Y-o-Y Growth Trend Analysis By End Usr , 2017-2021

    7.5. Absolute $ Opportunity Analysis By End Usr , 2022-2032

8. Global Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Drug

        9.2.3. By Indication

        9.2.4. By End Usr

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug

        9.3.3. By Indication

        9.3.4. By End Usr

    9.4. Key Takeaways

10. Latin America Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug

        10.2.3. By Indication

        10.2.4. By End Usr

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug

        10.3.3. By Indication

        10.3.4. By End Usr

    10.4. Key Takeaways

11. Europe Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug

        11.2.3. By Indication

        11.2.4. By End Usr

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug

        11.3.3. By Indication

        11.3.4. By End Usr

    11.4. Key Takeaways

12. Asia Pacific Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. India

            12.2.1.5. Malaysia

            12.2.1.6. Singapore

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of APAC

        12.2.2. By Drug

        12.2.3. By Indication

        12.2.4. By End Usr

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug

        12.3.3. By Indication

        12.3.4. By End Usr

    12.4. Key Takeaways

13. MEA Antisense Oligonucleotides Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug

        13.2.3. By Indication

        13.2.4. By End Usr

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug

        13.3.3. By Indication

        13.3.4. By End Usr

    13.4. Key Takeaways

14. Key Countries Antisense Oligonucleotides Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Drug

            14.1.2.2. By Indication

            14.1.2.3. By End Usr

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Drug

            14.2.2.2. By Indication

            14.2.2.3. By End Usr

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Drug

            14.3.2.2. By Indication

            14.3.2.3. By End Usr

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Drug

            14.4.2.2. By Indication

            14.4.2.3. By End Usr

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Drug

            14.5.2.2. By Indication

            14.5.2.3. By End Usr

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Drug

            14.6.2.2. By Indication

            14.6.2.3. By End Usr

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Drug

            14.7.2.2. By Indication

            14.7.2.3. By End Usr

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Drug

            14.8.2.2. By Indication

            14.8.2.3. By End Usr

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Drug

            14.9.2.2. By Indication

            14.9.2.3. By End Usr

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Drug

            14.10.2.2. By Indication

            14.10.2.3. By End Usr

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Drug

            14.11.2.2. By Indication

            14.11.2.3. By End Usr

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Drug

            14.12.2.2. By Indication

            14.12.2.3. By End Usr

    14.13. Malaysia

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Drug

            14.13.2.2. By Indication

            14.13.2.3. By End Usr

    14.14. Singapore

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Drug

            14.14.2.2. By Indication

            14.14.2.3. By End Usr

    14.15. Australia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Drug

            14.15.2.2. By Indication

            14.15.2.3. By End Usr

    14.16. New Zealand

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2021

            14.16.2.1. By Drug

            14.16.2.2. By Indication

            14.16.2.3. By End Usr

    14.17. GCC Countries

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2021

            14.17.2.1. By Drug

            14.17.2.2. By Indication

            14.17.2.3. By End Usr

    14.18. South Africa

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2021

            14.18.2.1. By Drug

            14.18.2.2. By Indication

            14.18.2.3. By End Usr

    14.19. Israel

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2021

            14.19.2.1. By Drug

            14.19.2.2. By Indication

            14.19.2.3. By End Usr

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug

        15.3.3. By Indication

        15.3.4. By End Usr

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Ionis Pharmaceuticals, Inc

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Sarepta Therapeutics

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Biogen

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Alnylam Pharmaceuticals, Inc

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Antisense Therapeutics Limited

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Isarna Therapeutics GmbH

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Arrowhead Pharmaceuticals, Inc

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Atlantic Pharmaceuticals, Inc

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Enzon Pharmaceuticals, Inc

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Bio-Path Holdings, Inc

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. Gene Signal International SA

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

        16.1.12. GlaxoSmithKline plc

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

        16.1.13. Geron Corporation

            16.1.13.1. Overview

            16.1.13.2. Product Portfolio

            16.1.13.3. Profitability by Market Segments

            16.1.13.4. Sales Footprint

            16.1.13.5. Strategy Overview

                16.1.13.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032

Table 3: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 4: Global Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032

Table 5: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032

Table 7: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 8: North America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032

Table 9: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032

Table 11: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 12: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032

Table 13: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032

Table 15: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 16: Europe Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032

Table 17: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 18: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032

Table 19: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 20: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032

Table 21: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 22: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Drug, 2017-2032

Table 23: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by Indication, 2017-2032

Table 24: MEA Antisense Oligonucleotides Market Value (US$ Mn) Forecast by End Usr , 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032

Figure 2: Global Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032

Figure 3: Global Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032

Figure 4: Global Antisense Oligonucleotides Market Value (US$ Mn) by Region, 2022-2032

Figure 5: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 6: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032

Figure 9: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032

Figure 10: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032

Figure 11: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 12: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 13: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 14: Global Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032

Figure 15: Global Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032

Figure 16: Global Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032

Figure 17: Global Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032

Figure 18: Global Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032

Figure 19: Global Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032

Figure 20: Global Antisense Oligonucleotides Market Attractiveness by Region, 2022-2032

Figure 21: North America Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032

Figure 22: North America Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032

Figure 23: North America Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032

Figure 24: North America Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032

Figure 25: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 26: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 27: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 28: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032

Figure 29: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032

Figure 30: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032

Figure 31: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 32: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 33: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 34: North America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032

Figure 35: North America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032

Figure 36: North America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032

Figure 37: North America Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032

Figure 38: North America Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032

Figure 39: North America Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032

Figure 40: North America Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032

Figure 41: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032

Figure 42: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032

Figure 43: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032

Figure 44: Latin America Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032

Figure 45: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 46: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 47: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 48: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032

Figure 49: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032

Figure 50: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032

Figure 51: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 52: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 53: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 54: Latin America Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032

Figure 55: Latin America Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032

Figure 56: Latin America Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032

Figure 57: Latin America Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032

Figure 58: Latin America Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032

Figure 59: Latin America Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032

Figure 60: Latin America Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032

Figure 61: Europe Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032

Figure 62: Europe Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032

Figure 63: Europe Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032

Figure 64: Europe Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032

Figure 65: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 66: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 67: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 68: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032

Figure 69: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032

Figure 70: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032

Figure 71: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 72: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 73: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 74: Europe Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032

Figure 75: Europe Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032

Figure 76: Europe Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032

Figure 77: Europe Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032

Figure 78: Europe Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032

Figure 79: Europe Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032

Figure 80: Europe Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032

Figure 81: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032

Figure 82: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032

Figure 83: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032

Figure 84: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032

Figure 85: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 86: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 87: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 88: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032

Figure 89: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032

Figure 90: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032

Figure 91: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 92: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 93: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 94: Asia Pacific Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032

Figure 95: Asia Pacific Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032

Figure 96: Asia Pacific Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032

Figure 97: Asia Pacific Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032

Figure 98: Asia Pacific Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032

Figure 99: Asia Pacific Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032

Figure 100: Asia Pacific Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032

Figure 101: MEA Antisense Oligonucleotides Market Value (US$ Mn) by Drug, 2022-2032

Figure 102: MEA Antisense Oligonucleotides Market Value (US$ Mn) by Indication, 2022-2032

Figure 103: MEA Antisense Oligonucleotides Market Value (US$ Mn) by End Usr , 2022-2032

Figure 104: MEA Antisense Oligonucleotides Market Value (US$ Mn) by Country, 2022-2032

Figure 105: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 106: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 107: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 108: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Drug, 2017-2032

Figure 109: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Drug, 2022-2032

Figure 110: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Drug, 2022-2032

Figure 111: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by Indication, 2017-2032

Figure 112: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by Indication, 2022-2032

Figure 113: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by Indication, 2022-2032

Figure 114: MEA Antisense Oligonucleotides Market Value (US$ Mn) Analysis by End Usr , 2017-2032

Figure 115: MEA Antisense Oligonucleotides Market Value Share (%) and BPS Analysis by End Usr , 2022-2032

Figure 116: MEA Antisense Oligonucleotides Market Y-o-Y Growth (%) Projections by End Usr , 2022-2032

Figure 117: MEA Antisense Oligonucleotides Market Attractiveness by Drug, 2022-2032

Figure 118: MEA Antisense Oligonucleotides Market Attractiveness by Indication, 2022-2032

Figure 119: MEA Antisense Oligonucleotides Market Attractiveness by End Usr , 2022-2032

Figure 120: MEA Antisense Oligonucleotides Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

RNA-Targeted Small Molecules Market

Published : September 2021

Healthcare

RNA Isolation and Enrichment Reagent Market

Published : November 2020

Healthcare

DNA/RNA Extraction Market

Published : March 2022

Google translate

Antisense Oligonucleotides Market